Corcept Therapeutics Incorporated (0I3Q)
Summary
0I3Q Chart
Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook
The transaction realized $1.9 million in gross proceeds on July 7, 2026, at a weighted average price of $93.13 per share. The disposition was a cashless exercise of 20,000 options at a strike price of $21.65, followed by an immediate open-market sale.
Corcept Therapeutics: Recent Relacorilant Rejection Aside, A Good News Story For Investors
Corcept Therapeutics maintains a Buy rating, supported by robust revenue growth, pipeline progress, and strong management execution. Relacorilant's FDA approval in ovarian cancer and likely approval in Cushing's syndrome could drive CORT revenues above $3 billion annually by decade's end. 2026 revenue guidance of $950M–$1.05B reflects >30% YoY growth, with minimal impact expected from generic competition due to pipeline innovation.
Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome
CORT resubmits relacorilant NDA for Cushing's syndrome, with updated analyses and data from multiple clinical studies supporting the filing.
Corcept Therapeutics Incorporated (0I3Q) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Corcept Therapeutics Incorporated ever had a stock split?
Corcept Therapeutics Incorporated Profile
| Biotechnology Industry | Healthcare Sector | Joseph K. Belanoff CEO | LSE Exchange | 218352102 CUSIP |
| US Country | 730 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Corcept Therapeutics Incorporated is a pioneer in the pharmaceutical industry with a focus on the discovery and development of medications for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders. Operating within the United States, the company has made significant strides in addressing complex health conditions by offering effective solutions. Founded in 1998 and headquartered in Menlo Park, California, Corcept has established itself as a leader in targeting illnesses related to hormonal imbalances and their consequences, thereby improving the quality of life for patients with unique and challenging medical conditions.
Products and Services
- Korlym tablets:
Korlym is an essential medication designed for the treatment of hyperglycemia secondary to hypercortisolism in adult patients diagnosed with endogenous Cushing's syndrome. This medication is particularly beneficial for those who have type 2 diabetes mellitus or glucose intolerance, and have either failed surgery or are not candidates for surgery. Through its targeted action, Korlym provides a critical healthcare solution to a niche patient demographic.
- Relacorilant:
Currently in phase III clinical trial, relacorilant is being developed as an advanced treatment solution for Cushing's syndrome. Beyond this application, relacorilant is also under investigation for its potential in treating adrenal cancer and cortisol excess (phase 1b clinical trial), prostate cancer (phase II clinical trial), and in combination with nab-paclitaxel for the treatment of platinum-resistant ovarian tumors (phase III clinical trial).
- Dazucorilant:
In its phase II clinical trial stage, dazucorilant is being explored as a possible therapeutic option for amyotrophic lateral sclerosis (ALS), a severe neurodegenerative disorder. This indication underscores Corcept's commitment to addressing complex neurologic conditions.
- Miricorilant:
Miricorilant is undergoing a phase IIb trial to assess its efficacy in treating nonalcoholic steatohepatitis (NASH), a liver disease. This development process aligns with Corcept's mission to provide treatments for metabolic disorders.
- Treatment for Antipsychotic Induced Weight Gain:
This investigative treatment, currently in phase I trial, addresses a significant side effect associated with antipsychotic medications: weight gain. With this initiative, Corcept aims to offer a solution to improve the overall management and quality of life for patients on antipsychotic therapy.
